Enrollment has finished ahead of schedule in a Phase 2 clinical trial testing Calluna Pharma‘s experimental antibody therapy CAL101 in people with idiopathic pulmonary fibrosis (IPF). The Phase 2 study, dubbed AURORA (NCT06736990), was designed to enroll about 150 adults…